Is Selank legal in Europe?

The legal status of Selank in Europe can be difficult to interpret definitively, as its classification depends on whether it is treated as a medicinal product, a research peptide, or a controlled substance.

Currently, Selank is not approved as a medicinal product by the European Medicines Agency (EMA) and does not have pan-European authorisation for the treatment of anxiety, cognitive disorders, or any other disease. Consequently, physicians in most European countries cannot prescribe an EMA-approved pharmaceutical version of Selank in routine clinical practice. In many cases, unapproved peptides like Selank fall under individual country regulations rather than uniform regulations across the European Union [1].

Is Selank legal in the European Union?

Selank is essentially not classified as an illegal or controlled substance within the European Union. Unlike drugs, opioids, anabolic steroids, and many psychoactive substances, Selank is not found on the main European lists of controlled substances [1,2].

However, the absence of controlled substance status does not imply approval for medical use.

In practice, Selank is in a regulatory grey area in many European countries. Some jurisdictions permit the sale and distribution of research peptides provided they are offered solely for laboratory or scientific research purposes and are not intended for human consumption [1,3].

Can Selank be bought in Europe?

Selank is available from many European suppliers offering peptides for research purposes. However, commercial availability does not imply regulatory approval.

The current regulatory situation can be summarised as follows:

As the regulations governing peptides vary between EU Member States, issues relating to import, sale, product labelling and the stated intended use may be subject to national regulations and local supervisory authorities.

Is Selank Legal in the UK?

Post-Brexit, the United Kingdom operates under an independent regulatory framework overseen by the Medicines and Healthcare products Regulatory Agency (MHRA).

The available information indicates that Selank is not authorised as a medicinal product by the MHRA and is not classified as a controlled substance under the Misuse of Drugs Act [3,4].

Research peptides offered without medical claims may, in principle, be sold for legitimate laboratory and scientific purposes. However, promoting Selank as a product intended for human use is subject to separate regulatory requirements and may result in enforcement action by the MHRA [3,4].

Why is Selank considered a product operating in a regulatory grey area?

There are several factors that contribute to Selank’s unique legal status.

Firstly, Selank has primarily been studied in Russia and some Eastern European countries, rather than within extensive international clinical development programmes usually required for EMA approval [5].

Secondly, although published studies suggest potential anxiolytic and cognitive-enhancing effects, the current evidence base is relatively limited compared with approved pharmaceutical products [6–8].

Finally, peptide therapies pose particular challenges relating to the consistency of the manufacturing process, quality control and long-term safety assessment. Regulatory authorities typically require extensive clinical and safety data before approving new peptide drugs [9].

Current Scientific and Regulatory Proposal

As of 2026, Selank is essentially not recognised as an illegal substance in Europe, but it is also not an EMA-approved medicine. Its availability in some European countries is mainly in the context of scientific research, and regulatory requirements may vary significantly between different jurisdictions.

Is Selank approved by the FDA?

Is Selank approved by the FDA?

No. Selank has not been approved by the US Food and Drug Administration (FDA) for the treatment of anxiety, cognitive disorders, depression, sleep disorders, or any other condition [10–12].

Although Selank has been investigated for several potential therapeutic applications, it has not undergone the FDA approval process required for it to be marketed as a prescription drug in the United States.

What Does FDA Approval Mean?

FDA approval requires the submission of robust evidence demonstrating that the product:

• is effective for a specific indication,
• is safe at recommended doses,
• is manufactured in accordance with rigorous quality standards,
• has appropriate clinical trials evaluating both benefits and risks.

To date, Selank has not completed the full regulatory process required to obtain approved drug status in the United States [10,11].

Why isn’t Selank approved by the FDA?

Limited Clinical Development

Most research on Selank has been conducted in Russia and neighbouring countries, with a significant portion of the published literature consisting of small clinical trials, animal experiments, and mechanistic studies [5–8].

Although these studies have yielded promising results in terms of reducing anxiety and improving cognitive function, they do not constitute the large-scale Phase I, II and III clinical development programmes typically required by the FDA.

Insufficient safety data for long-term use

The FDA typically requires detailed information regarding long-term safety, manufacturing consistency, pharmacokinetics, and potential adverse effects.

The agency indicated that the available information regarding the safety of Selank acetate is insufficient, and peptide products may pose risks related to aggregation, immunogenicity, and the presence of peptide impurities [10].

Lack of Commercial Drug Development Programmes

Obtaining FDA approval is a lengthy and costly process, often requiring many years of clinical trials and significant financial investment. Currently, no pharmaceutical manufacturer has completed this process for Selank.

Are Semax and Selank approved by the FDA?

No.

Neither Selank nor Semax have received FDA approval for any medical indication in the United States [10–12].

Both peptides have been investigated for neurocognitive and anxiolytic applications and are available under different regulatory frameworks in some countries. However, neither currently holds FDA-approved drug status.

Does the lack of FDA approval mean Selank doesn't work?

No.

A lack of FDA approval does not automatically mean a compound is ineffective. It simply means that sufficient evidence has not been presented to meet the FDA's requirements for approval.

Several published studies suggest that Selank may exhibit anxiolytic and neuroregulatory properties, including effects on GABA-ergic signalling, endogenous opioid peptides, and pathways associated with neuroplasticity [6-8].

However, available evidence remains limited, and further large-scale human studies are needed to confirm safety and efficacy according to current regulatory standards.

Current Scientific and Regulatory Proposal

As of 2026, Selank is not approved by the FDA and has no approved medical indications in the United States. Similarly, Semax is also not FDA-approved. While both peptides continue to generate scientific interest due to their potential neurobiological effects, obtaining FDA approval would necessitate further clinical development and the accumulation of extensive long-term safety data.

Disclaimer

These contents are for educational and informational purposes only and should not be interpreted as legal or medical advice. Regulations governing peptides can change and vary significantly between countries and jurisdictions. Selank is not approved by either the European Medicines Agency (EMA) or the US Food and Drug Administration (FDA) for any medical indication. A significant portion of the available data on Selank comes from preclinical studies and limited human trials.

For research purposes only: Selank products offered by Semax Polska are intended solely for laboratory and scientific research. They are not authorised for human consumption, medical use, diagnosis, treatment or the prevention of any disease. Anyone interested in research peptides should familiarise themselves with current national regulations and consult suitably qualified specialists on legal and medical matters.

References

[1] European Union Peptide Laws & Regulations. (2026). European Union Peptide Regulations and Legal Status Overview. https://peptidelaws.com/laws/european-union

[2] Selank. (2026). Wikipedia. https://en.wikipedia.org/wiki/Selank

[3] Selank UK: Complete Research Guide. (2026). Peptides Lab UK. https://peptideslabuk.com/selank-uk-complete-research-guide-2026/

[4] Are Peptides Legal in the UK? Research Use, Regulation and What You Need to Know. (2026). Peptides Lab UK. https://peptideslabuk.com/are-peptides-legal-in-the-uk-research-use-regulation-and-what-you-need-to-know-2026/

[5] Deigin, V. I. (2022). Development of Peptide Biopharmaceuticals in Russia. Frontiers in Pharmacology, 13, 827793. https://doi.org/10.3389/fphar.2022.827793

[6] Vyunova, T. V., Andreeva, L., Shevchenko, K., & Myasoedov, N. F. (2018). Peptide-Based Anxiolytics: The Molecular Aspects of Heptapeptide Selank Biological Activity. Protein and Peptide Letters, 25(10), 914–923. https://doi.org/10.2174/0929866525666180925144642

[7] Zozulia, A. A., Neznamov, G. G., Siuniakov, T. S., Kost, N. V., Gabaeva, M. V., Sokolov, O. Y., Serebriakova, E. V., Siranchieva, O. A., Andriushenko, A. V., Telesheva, E. S., Siuniakov, S. A., Smulevich, A. B., Myasoedov, N. F., & Seredenin, S. B. (2008). Efficacy and Possible Mechanisms of Action of a New Peptide Anxiolytic Selank in the Therapy of Generalised Anxiety Disorders and Neurasthenia. Journal of Neurology and Psychiatry named after S.S. Korsakov, 108(4), 38–48. https://pubmed.ncbi.nlm.nih.gov/18454096/

[8] Levitskaya, N. G., Andreeva, L. A., Mezentseva, M. V., Shapoval, I. M., Podchernyaeva, R. Y., Shcherbenko, V. E., Potapova, L. A., Russu, L. I., Ershov, F. I., & Myasoedov, N. F. (2010). Intranasal Administration of the Peptide Selank Regulates BDNF Expression in the Rat Hippocampus In Vivo. Doklady Biological Sciences, 431, 79–82.

[9] Unregulated Peptide Use in the Age of Biohacking: Digital Promotion, Gray-Market Access, and Emerging Public Health Risks. (2026). Cureus. https://www.cureus.com/articles/494964-unregulated-peptide-use-in-the-age-of-biohacking-digital-promotion-gray-market-access-and-emerging-public-health-risks

[10] U.S. Food and Drug Administration. (2026). Certain Bulk Drug Substances for Use in Compounding That May Present Significant Safety Risks. https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks

[11] Empire Medical Training. (2026). Selank: Uses, Benefits & Clinical Overview. https://www.empiremedicaltraining.com/antiaging-regenerative-workshops/resources/peptide-therapy/selank/

[12] Innerbody. (2026). Selank Peptide: Benefits, Safety & Buying Advice. https://www.innerbody.com/selank-peptide